Business
Parsortix outperforms other CTC systems in RCC
Parsortix outperforms other CTC systems in RCC.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n RNS Number : 2737E\n Angle PLC\n 27 February 2020\n \n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 27 February 2020\n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n PARSORTIX OUTPERFORMS OTHER CTC SYSTEMS IN RENAL CELL CARCINOMA\n \n \n \n \n \n Publication in International Journal of Molecular Sciences demonstrates benefits of Parsortix \"unbiased\" CTC enrichment process \n \n \n \n \n \n Workflow combines Parsortix with downstream process for single cell analysis of each individual cancer cell\n \n \n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that Istituto Nazionale Tumori di Milano, Milano, Italy has published results of work, which assessed the performance of Parsortix® in renal cell carcinoma (RCC) demonstrating key advantages of the Parsortix system. \n \n \n \n \n \n The disease is often asymptomatic (few or no symptoms) and about 30% of patients with RCC present with metastatic disease. Their prognosis is poor with an overall 5-year survival rate of less than 20%. A number of targeted therapies have recently become available and a liquid biopsy to determine whether such treatments might benefit individual patients would be highly valuable.\n \n \n \n \n \n Legacy circulating tumor cell (CTC) antibody-based systems have been ineffective in RCC due to low expression of epithelial markers on the CTCs. Istituto Nazionale Tumori di Milano compared the performance of a Parsortix-based approach with a leading alternative CTC system. The Parsortix system was combined with a single cell picking system so that individual CTCs could for the first time, in this tumor type, be harvested and then analysed to assess the heterogeneity of the CTCs.\n \n \n \n \n \n The Parsortix system greatly out-performed the alternative approach and, being a marker-independent approach for CTC enrichment, it was described in the publication as being \"instrumental for increasing CTC detection and for being able to separately identify the sub-populations by immunostaining\".\n \n \n \n \n \n The pilot study suggested that even the presence of a single CTC in a blood sample prior to treatment may predict a reduced progression free survival...